ClinicalTrials.gg

Program

NNC0662-0419

A development code.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Novo Nordisk.

Furthest: phase 2, since Sep 18, 20256 company-led studies, 4 open or runningNext primary completion: Dec 14, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk64 open or runningphase 2since Sep 18, 2025Dec 12, 2024Dec 14, 2026phase 2 · NCT07184632

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2024First study: phase 1 study in OverweightFirst studyNCT06737536 · 100 enrolled · United States
  2. Jul 28, 2025Phase 1 study in OverweightNCT07101783 · 100 enrolled · United States
  3. Sep 18, 2025Phase 2 study in OverweightNCT07184632 · 224 enrolled · United States
  4. Feb 11, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07415954 · 270 planned · United States, Croatia, Hungary and more
  5. Apr 6, 2026Phase 1 study in OverweightNCT07525791 · 41 enrolled · United States
  6. Jun 5, 2026Phase 2 study in ObesityNCT07639021 · 233 enrolled · United States, Puerto Rico

Ahead

  1. Dec 14, 2026Primary completion: phase 2 study in OverweightNCT07184632
  2. May 2, 2027Primary completion: phase 1 study in OverweightNCT07525791
  3. Jun 14, 2027Primary completion: phase 2 study in ObesityNCT07639021
  4. Sep 3, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07415954

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07639021Obesity · United States, Puerto Rico2Active, not recruitingJun 14, 2027233
NCT07525791Overweight · United States1Active, not recruitingMay 2, 202741
NCT07415954Diabetes Mellitus, Type 2 · United States, Croatia, Hungary and more2RecruitingSep 3, 2027270
NCT07184632Overweight · United States2Active, not recruitingDec 14, 2026224
NCT07101783Overweight · United States1CompletedOct 31, 2025100
NCT06737536Overweight · United States1CompletedJul 26, 2025100

How it is read

Names in the registry

  • “NNC0662-0419”, 6 entries

Codes read as this program: NNC06620419.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.